Zimmer contemplating buyout of surgeons' royalty contracts

From the Financial Times article:

Zimmer, one of the world’s biggest makers of orthopaedic implants, is reviewing its contracts with hundreds of US surgeons in a move that could take the company’s bill for clearing up a legal case last year to more than $450m.

Under procedures intended to make its dealings with surgeons with whom it has consultancy relationships more transparent, Zimmer is considering terminating its royalty contracts with many of these doctors.

Click here to access the article.